RT Journal Article
T1 Survival analysis in high-grade glioma: the role of salvage surgery
A1 Lopez, A. J. Vargas
A1 Carballal, C. Fernandez
A1 Mele, M. Valera
A1 Rodriguez-Boto, G.
K1 High-grade glioma
K1 Recurrence
K1 Extent of resection
K1 Reoperation
K1 Salvage surgery
K1 Survival
K1 Recurrent glioblastoma
K1 2nd surgery
K1 Resection
K1 Reoperation
K1 Reirradiation
K1 Multicenter
K1 Bevacizumab
K1 Radiotherapy
K1 Temozolomide
K1 Organization
AB Objectives: This study addresses the survival of consecutive patients with high-grade gliomas treated at the same institution over a period of 10 years. We analyse the importance of associated factors and the role of salvage surgery at the time of progression.Methods: We retrospectively analysed a series of patients with World Health Organization (WHO) grade III/IV gliomas treated between 2008 and 2017 at Hospital Gregorio Maranon (Madrid, Spain). Clinical, radiological, and anatomical pathology data were obtained from patient clinical histories.Results: Follow-up was completed in 233 patients with HGG. Mean age was 62.2 years. The median survival time was 15.4 months. Of 133 patients (59.6%) who had undergone surgery at the time of diagnosis, 43 (32.3%) underwent salvage surgery at the time of progression. This subgroup presented longer overall survival and survival after progression. Higher Karnofsky Performance Status score at diagnosis, a greater extent of surgical resection, and initial diagnosis of WHO grade III glioma were also associated with longer survival.Conclusions: About one-third of patients with HGG may be eligible for salvage surgery at the time of progression. Salvage surgery in this subgroup of patients was significantly associated with longer survival. (c) 2020 Sociedad Espanola de Neurologia. Published by Elsevier Espana, S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
PB Elsevier espana slu
SN 0213-4853
YR 2022
FD 2022-12-22
LK https://hdl.handle.net/10668/24913
UL https://hdl.handle.net/10668/24913
LA es
DS RISalud
RD Apr 5, 2025